Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Chronic hepatitis B: Advances in treatment.

Literature DB >> 24868322

Chronic hepatitis B: Advances in treatment.

Teresa Antonia Santantonio¹, Massimo Fasano¹.

Abstract

Treatment of chronic hepatitis B (CHB) has markedly improved in the last 15 years due to the availability of direct antivirals which greatly increase therapeutic options. Currently, there are two classes of agents licensed for CHB treatment: standard or pegylated interferon alpha (IFN or Peg-IFN) and five nucleoside/nucleotide analogues (NAs). Long-term treatment with NAs is the treatment option most often used in the majority of CHB patients. Entecavir and tenofovir, the most potent NAs with high barrier to resistance, are recommended as first-line monotherapy by all major treatment guidelines and can lead to long-lasting virological suppression, resulting in histological improvement or reversal of advanced fibrosis and reduction in disease progression and liver-related complications. In this review, we focus on current treatment strategies of chronic hepatitis B and discuss the most recent efficacy and safety data from clinical trials and real life clinical practice. Recent findings of response-guided approaches are also discussed.

Entities: Chemical Disease Species

Keywords: Antiviral resistance; Antiviral therapy; Chronic hepatitis; Nucleos(t)ide analogues; Peg-interferon

Year: 2014 PMID： 24868322 PMCID： PMC4033286 DOI： 10.4254/wjh.v6.i5.284

Source DB: PubMed Journal: World J Hepatol

41 in total

1. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C.

Authors: Y-F Liaw; J-D Jia; H L Y Chan; K H Han; T Tanwandee; W L Chuang; D M Tan; X Y Chen; E Gane; T Piratvisuth; L Chen; Q Xie; J J Y Sung; C Wat; C Bernaards; Y Cui; P Marcellin
Journal: Hepatology Date: 2011-11 Impact factor: 17.425

2. Evaluation of susceptibility locus for response to interferon-α based therapy in chronic hepatitis B patients in Chinese.

Authors: Xiaopan Wu; Zhenhui Xin; Xilin Zhu; Liping Pan; Zhuo Li; Hui Li; Ying Liu
Journal: Antiviral Res Date: 2011-12-19 Impact factor: 5.970

3. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B.

Authors: Milan J Sonneveld; Vincent Rijckborst; Stefan Zeuzem; E Jenny Heathcote; Krzysztof Simon; Hakan Senturk; Suzan D Pas; Bettina E Hansen; Harry L A Janssen
Journal: Hepatology Date: 2012-04-25 Impact factor: 17.425

4. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.

Authors: Patrick Marcellin; Edward Gane; Maria Buti; Nezam Afdhal; William Sievert; Ira M Jacobson; Mary Kay Washington; George Germanidis; John F Flaherty; Raul Aguilar Schall; Jeffrey D Bornstein; Kathryn M Kitrinos; G Mani Subramanian; John G McHutchison; E Jenny Heathcote
Journal: Lancet Date: 2012-12-10 Impact factor: 79.321

5. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.

Authors: Yun-Fan Liaw; I-Shyan Sheen; Chuan-Mo Lee; Ulus Salih Akarca; George V Papatheodoridis; Florence Suet-Hing Wong; Ting-Tsung Chang; Andrzej Horban; Chia Wang; Peter Kwan; Maria Buti; Martin Prieto; Thomas Berg; Kathryn Kitrinos; Ken Peschell; Elsa Mondou; David Frederick; Franck Rousseau; Eugene R Schiff
Journal: Hepatology Date: 2010-10-27 Impact factor: 17.425

6. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function.

Authors: Christian M Lange; Jörg Bojunga; Wolf Peter Hofmann; Katrin Wunder; Ulrike Mihm; Stefan Zeuzem; Christoph Sarrazin
Journal: Hepatology Date: 2009-12 Impact factor: 17.425

7. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.

Authors: Erik H C J Buster; Bettina E Hansen; George K K Lau; Teerha Piratvisuth; Stefan Zeuzem; Ewout W Steyerberg; Harry L A Janssen
Journal: Gastroenterology Date: 2009-09-06 Impact factor: 22.682

8. Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B.

Authors: Pietro Lampertico; Mauro Viganò; Giovan Giuseppe Di Costanzo; Evangelista Sagnelli; Massimo Fasano; Vito Di Marco; Sara Boninsegna; Patrizia Farci; Silvia Fargion; Tiziana Giuberti; Claudio Iannacone; Loredana Regep; Benedetta Massetto; Floriana Facchetti; Massimo Colombo
Journal: Gut Date: 2012-08-02 Impact factor: 23.059

9. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.

Authors: Paola Piccolo; Ilaria Lenci; Luigi Demelia; Franco Bandiera; Maria R Piras; Giorgio Antonucci; Lorenzo Nosotti; Terenzio Mari; Adriano De Santis; Maria L Ponti; Orazio Sorbello; Fabio Iacomi; Mario Angelico
Journal: Antivir Ther Date: 2009

10. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response.

Authors: Roeland Zoutendijk; Jurriën G P Reijnders; Ashley Brown; Fabien Zoulim; David Mutimer; Katja Deterding; Jörg Petersen; Wolf Peter Hofmann; Maria Buti; Teresa Santantonio; Florian van Bömmel; Pierre Pradat; Ye Oo; Marc Luetgehetmann; Thomas Berg; Bettina E Hansen; Heiner Wedemeyer; Harry L A Janssen
Journal: Hepatology Date: 2011-08 Impact factor: 17.425

12 in total

Chronic hepatitis B: Advances in treatment.

1. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C.

2. Evaluation of susceptibility locus for response to interferon-α based therapy in chronic hepatitis B patients in Chinese.

3. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B.

4. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.

5. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.

6. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function.

7. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.

8. Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B.

9. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.

10. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response.

Review 1. Gene therapeutic approaches to inhibit hepatitis B virus replication.

Review 2. Nucleos(t)ide analogues to treat hepatitis B virus-related hepatocellular carcinoma after radical resection.

Review 3. Prevention of hepatitis B virus infection: from the past to the future.

4. Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy.

5. Detection and analysis of resistance mutations of hepatitis B virus.

Review 6. Clinical Advances in Fibrosis Progression of Chronic Hepatitis B and C.

Review 7. Update on Hepatitis B Virus Infection: Focus on Treatment.

Review 8. Hepatitis B and its Relationship With Oxidative Stress.

Review 9. Hepatitis B virus and its sexually transmitted infection - an update.

10. Genetic Evidence for Genotoxic Effect of Entecavir, an Anti-Hepatitis B Virus Nucleotide Analog.